Suppr超能文献

夏科-马里-图思5型周围神经病——已停用章节,仅作历史参考

Charcot-Marie-Tooth Neuropathy X Type 5 – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY

作者信息

Kim Jong-Won, Kim Hee-Jin

机构信息

Department of Laboratory Medicine & Genetics, Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Abstract

UNLABELLED

NOTE: THIS PUBLICATION HAS BEEN RETIRED. THIS ARCHIVAL VERSION IS FOR HISTORICAL REFERENCE ONLY, AND THE INFORMATION MAY BE OUT OF DATE.

CLINICAL CHARACTERISTICS

X-linked Charcot-Marie-Tooth neuropathy type 5 (CMTX5), part of the spectrum of -related disorders, is characterized by peripheral neuropathy, early-onset (prelingual) bilateral profound sensorineural hearing loss, and optic neuropathy. The onset of peripheral neuropathy is between ages five and 12 years. The lower extremities are affected earlier and more severely than upper extremities. Initial manifestations often include foot drop or gait disturbance. Onset of visual impairment is between ages seven and 20 years. Intellect and life span are normal. Carrier females do not have findings of CMTX5.

DIAGNOSIS/TESTING: Diagnosis is based on clinical findings, family history consistent with X-linked inheritance, and identification of a pathogenic variant in , the only gene in which pathogenic variants are known to cause CMTX5.

MANAGEMENT

Peripheral neuropathy, hearing loss, and visual impairment are managed in a routine manner. Regular neurologic and ophthalmologic evaluations to monitor symptom development and disease progression. Medications known to cause acquired peripheral neuropathy. It is appropriate to evaluate at-risk males at birth with detailed audiometry to assure early diagnosis and treatment of hearing loss.

GENETIC COUNSELING

CMTX5 is inherited in an X-linked manner. Carrier women have a 50% chance of transmitting the pathogenic variant in each pregnancy. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and typically will not be affected. Males pass the pathogenic variant to all of their daughters and none of their sons. Carrier testing for at-risk family members and prenatal testing for a pregnancy at increased risk are possible if the pathogenic variant has been identified in the family.

摘要

未标注

注意:本出版物已停用。此存档版本仅用于历史参考,信息可能过时。

临床特征

X连锁型夏科-马里-图思神经病变5型(CMTX5)是相关疾病谱的一部分,其特征为周围神经病变、早发性(语言前)双侧重度感音神经性听力丧失和视神经病变。周围神经病变发病年龄在5至12岁之间。下肢比上肢更早且更严重地受到影响。初始表现通常包括足下垂或步态障碍。视力损害发病年龄在7至20岁之间。智力和寿命正常。携带致病基因的女性没有CMTX5的表现。

诊断/检测:诊断基于临床发现、与X连锁遗传一致的家族史以及在已知致病基因变异可导致CMTX5的唯一基因中鉴定出致病变异。

管理

以常规方式处理周围神经病变、听力丧失和视力损害。定期进行神经学和眼科评估以监测症状发展和疾病进展。已知某些药物可导致获得性周围神经病变。对有风险的男性在出生时进行详细听力测定评估以确保早期诊断和治疗听力丧失是合适的。

遗传咨询

CMTX5以X连锁方式遗传。携带致病基因的女性在每次怀孕时有50%的机会传递致病基因变异。继承致病基因变异的男性会患病;继承致病基因变异的女性将成为携带者且通常不会患病。男性将致病基因变异传给所有女儿,不传给任何儿子。如果已在家族中鉴定出致病基因变异,则可为有风险的家庭成员进行携带者检测,并对风险增加的妊娠进行产前检测。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验